Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
SPECT/CT in musculoskeletal infections.
Thang SP, Tong AK, Lam WW, Ng DC. Thang SP, et al. Semin Musculoskelet Radiol. 2014 Apr;18(2):194-202. doi: 10.1055/s-0034-1371020. Epub 2014 Apr 8. Semin Musculoskelet Radiol. 2014. PMID: 24715450 Review.
A rare case of thymoma first detected on gallium-68 PSMA PET/CT.
Huang HL, Dharmawan AR, Tan CJ, Thang SP. Huang HL, et al. Among authors: thang sp. Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):2148-2149. doi: 10.1007/s00259-017-3785-2. Epub 2017 Aug 1. Eur J Nucl Med Mol Imaging. 2017. PMID: 28765999 No abstract available.
Current Status and Growth of Nuclear Theranostics in Singapore.
Huang HL, Tong AKT, Thang SP, Yan SX, Lam WWC, Loke KSH, Tang CYL, Cheng LTJ, Ooi GSK, Low HC, Magsombol BM, Tham WY, Goh CXY, Tan CJ, Khor YM, Zaheer S, Bharadwaj P, Xie W, Ng DCE. Huang HL, et al. Among authors: thang sp. Nucl Med Mol Imaging. 2019 Apr;53(2):96-101. doi: 10.1007/s13139-019-00580-3. Epub 2019 Jan 25. Nucl Med Mol Imaging. 2019. PMID: 31057680 Free PMC article.
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial.
Buteau JP, Martin AJ, Emmett L, Iravani A, Sandhu S, Joshua AM, Francis RJ, Zhang AY, Scott AM, Lee ST, Azad AA, McJannett MM, Stockler MR, Williams SG, Davis ID, Hofman MS; TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Buteau JP, et al. Lancet Oncol. 2022 Nov;23(11):1389-1397. doi: 10.1016/S1470-2045(22)00605-2. Epub 2022 Oct 16. Lancet Oncol. 2022. PMID: 36261050 Clinical Trial.
28 results